


Anti-CDH6 Recombinant Antibody Products

Anti-CDH6 Products
- Human Anti-CDH6 Recombinant Antibody (TAB-405LC) (TAB-405LC)
-
- Species Reactivity: Human
- Type: Human IgG
- Application: ELISA, FC
- Human Anti-CDH6 Recombinant Antibody; scFv Fragment (TAB-405LC-S(P)) (TAB-405LC-S(P))
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA, FC
- Human Anti-CDH6 Recombinant Antibody; Fab Fragment (TAB-405LC-F(E)) (TAB-405LC-F(E))
-
- Species Reactivity: Human
- Type: Human Fab
- Application: ELISA, FC
-
- Species Reactivity: Human, Rat
- Type: Mouse IgG1
- Application: ICC, IHC-Fr, IHC-P, WB
- Human Anti-CDH6 Recombinant Antibody (VS-0723-WK69) (VS-0723-WK69)
-
- Derivation: Chimeric (rabbit/human)
- Species Reactivity: Human
- Type: Chimeric (rabbit/human) IgG1
- Application: FC
- Human Anti-CDH6 Recombinant Antibody (HPAB-0391-FY) (HPAB-0391-FY)
-
- Species Reactivity: Human, Monkey, Rat, Mouse
- Type: Human IgG
- Application: FC, ELISA, Activ
- Human Anti-CDH6 Recombinant Antibody (HPAB-0392-FY) (HPAB-0392-FY)
-
- Species Reactivity: Human, Monkey, Rat, Mouse
- Type: Human IgG
- Application: FC, ELISA, Activ
-
- Species Reactivity: Human
- Type: Human IgG1
- Application: ELISA, FC
-
- Species Reactivity: Human
- Type: Human Fab
- Application: ELISA, FC
- Human Anti-CDH6 Recombinant Antibody; Fab Fragment (HPAB-0392-FY-F(E)) (HPAB-0392-FY-F(E))
-
- Species Reactivity: Human, Monkey, Rat, Mouse
- Type: Human Fab
- Application: FC, ELISA, Activ
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA, FC
- Human Anti-CDH6 Recombinant Antibody; scFv Fragment (HPAB-0391-FY-S(P)) (HPAB-0391-FY-S(P))
-
- Species Reactivity: Human, Monkey, Rat, Mouse
- Type: Human scFv
- Application: FC, ELISA, Activ
- Human Anti-CDH6 Recombinant Antibody; scFv Fragment (HPAB-0392-FY-S(P)) (HPAB-0392-FY-S(P))
-
- Species Reactivity: Human, Monkey, Rat, Mouse
- Type: Human scFv
- Application: FC, ELISA, Activ
- Human Anti-CDH6 Recombinant Antibody; Fab Fragment (HPAB-0391-FY-F(E)) (HPAB-0391-FY-F(E))
-
- Species Reactivity: Human, Monkey, Rat, Mouse
- Type: Human Fab
- Application: FC, ELISA, Activ
-
- Species Reactivity: Human
- Target: CDH6
- Host Animal: Human
- Application: ELISA, FC, Cell-uptake
- Anti-CDH6 Immunohistochemistry Kit (VS-0525-XY1300)
-
- Species Reactivity: Human
- Target: CDH6
- Application: IHC
-
- Derivation: Phage display library
- Species Reactivity: Human
- Type: Rabbit IgG
- Application: WB, IP
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs is proud to offer an extensive selection of cutting-edge recombinant antibodies specifically targeting CDH6, playing a pivotal role in advancing biomedical research and innovation. Utilizing state-of-the-art technologies and sophisticated development platforms, we guarantee that every product adheres to the strictest standards of quality, consistency, and performance. Our commitment to supporting scientific progress is reflected in the wide array of recombinant solutions we provide, all carefully designed to deliver outstanding reliability and value. Beyond offering premium-grade antibodies, Creative Biolabs is equally dedicated to delivering exceptional technical support, assisting researchers at every step-from project design to data interpretation. By choosing Creative Biolabs as your partner, you gain not only access to innovative research tools but also the backing of a dependable, forward-thinking collaborator in your scientific endeavors.
CDH6: A Key Target in Cancer Progression and Therapeutic Development
CDH6 (Cadherin 6) is a cell adhesion molecule primarily expressed in kidney tissues, but its role extends to various types of cancer. As a member of the cadherin family, CDH6 is involved in maintaining cellular integrity and communication, which are essential for tissue structure and function. In the context of disease, elevated expression of CDH6 has been associated with several malignancies, including renal cell carcinoma (RCC), where it plays a pivotal role in tumor progression and metastasis. The aberrant overexpression of CDH6 disrupts normal cell adhesion, contributing to cancer cell migration and invasion. Additionally, CDH6 has shown potential as a therapeutic target, with ongoing research exploring its role in cancer diagnostics and treatment. Targeting CDH6 may allow for the development of novel therapies aimed at inhibiting tumor growth and improving patient outcomes. Its selective expression in specific cancer cells also makes it a promising candidate for targeted therapies, minimizing damage to healthy tissues while enhancing the effectiveness of treatments.
Alternative Names
Complement CAD6; KCAD; CDH6
Background
This gene encodes a member of the cadherin superfamily. Cadherins are membrane glycoproteins that mediate homophilic cell-cell adhesion and play critical roles in cell differentiation and morphogenesis. The encoded protein is a type II cadherin and may play a role in kidney development as well as endometrium and placenta formation. Decreased expression of this gene may be associated with tumor growth and metastasis.
Plasma proteins
Membrane
Cell type enhanced (Proximal tubular cells, Smooth muscle cells, Excitatory neurons, Pancreatic endocrine cells, Oligodendrocyte precursor cells, Cholangiocytes, Sertoli cells)
Not detected in immune cells
Cell line enriched (EFO-21)
Anti-CDH6 rAb Products
At Creative Biolabs, our core mission is to drive progress in scientific discovery by offering high-performance recombinant antibodies against CDH6. We are dedicated to equipping researchers with not only top-tier, dependable products but also the resources and guidance needed to ensure experimental success. Through a combination of scientific excellence, product reliability, and personalized technical assistance, we aim to empower research initiatives and foster meaningful breakthroughs across a wide range of biomedical fields.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-405LC | Human Anti-CDH6 Recombinant Antibody (TAB-405LC) | Human | Human | ELISA; FC |
PABC-397 | Human Anti-CDH6 Recombinant Antibody (clone Ab-HKT288) | Human | Human | ELISA; FC |
HPAB-0391-FY | Human Anti-CDH6 Recombinant Antibody (HPAB-0391-FY) | Human; Monkey; Rat; Mouse | Human | FC; ELISA; Activ |
ZG-0979F | Mouse Anti-CDH6 Recombinant Antibody (clone 2B6) | Human; Rat | Mouse | ICC; IHC-F; IHC-P; WB |
VS-0723-WK69 | Human Anti-CDH6 Recombinant Antibody (VS-0723-WK69) | Human | Human | FC |
Customer Reviews

Human Anti-CDH6 Recombinant Antibody (VS-0723-WK69)
(CAT#: VS-0723-WK69)

Human Anti-CDH6 Recombinant Antibody (HPAB-0391-FY)
(CAT#: HPAB-0391-FY)

Human Anti-CDH6 Recombinant Antibody (clone Ab-HKT288)
(CAT#: PABC-397)
rAb Production
With years of experience in recombinant antibody development and optimization, we are committed to offering outstanding service. We supply high-quality recombinant antibody products, maintaining strict standards while ensuring fast delivery.
Featured Anti-CDH6 Recombinant Antibody Production Platforms
Fig.1 Milligram-scale recombinant antibody production.
Fig.2 Gram-scale recombinant antibody production.
rAb Modalities
Creative Biolabs is dedicated to empowering the research community with an extensive portfolio of cutting-edge recombinant antibodies, available in a range of customizable formats to suit diverse experimental needs. Backed by deep expertise in antibody engineering and molecular design, our team delivers innovative solutions tailored to meet the specific challenges of your research. In addition to our high-performance antibody products, we offer flexible custom services and technical support to help you achieve optimal results at every stage of your project.
Fig.3 Full Length Anti-CDH6 Recombinant Antibody Production and Modalities.
Drug Information Targeting CDH6
Table 1. Therapeutic approaches targeting CDH6 in clinical development.
Research phase | Company | Classification | Indications | Details |
Phase II/III | Daiichi Sankyo | Drug Conjugates |
Cancer; Carcinoma, primary peritoneal |
Daiichi Sankyo's anti-CDH6 ADC is in late-stage trials for cancer and will be co-developed globally with Merck, excluding Japan. |
Phase I | Multitude | Drug Conjugates | Cancer; Solid tumor | OnCusp Therapeutics is developing a CDH6-targeting ADC with exatecan for advanced tumors, licensed from Multitude in 2022. |
Phase I | MorphoSys | Drug Conjugates | Cancer | Novartis was investigating HKT-288, a CDH6-targeting ADC, in early trials for ovarian and renal cancers, but the study was suspended in 2017 and terminated in 2018. |
If you need more information about the CDH6 target, please don't hesitate to contact us by phone or email. Our experienced team is ready to help answer any questions or troubleshoot issues you encounter during your experiments, providing the support necessary for your research success.